体外诊断药物（IVD）市场趋势及最新资讯：2024年3月

In Vitro Diagnostic (IVD) Trends and Market Update: March 2024

出版日期: 2024年03月26日 | 出版商:

Kalorama Information | 英文 55 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

诊断测试是医疗保健的基石，帮助医生诊断医疗状况并决定治疗方案。虽然 COVID-19 测试对总收入产生了影响，但核心诊断领域总体上出现了成长。儘管市场因新产品、全球医疗保健支出变化、监管变化和疾病趋势等因素而不断变化，但它仍然具有弹性。

该行业关注的关键成长领域包括下一代定序 (NGS)、个人化医疗和质谱。免疫化学、即时检测 (POC) 和分子诊断也引起了人们的极大兴趣，并有望在 IVD 的未来中发挥重要作用。体外诊断（IVD）市场是一个充满活力的市场，其特点是不断的技术创新。

该报告考察了体外诊断药物（IVD）市场并提供了有关市场趋势的最新资讯。它还总结了主要公司进入市场的趋势。

Diagnostic testing has become a fundamental aspect of healthcare, aiding physicians in diagnosing conditions and determining treatments. Despite a decline in COVID-19 testing affecting total revenues, core diagnostic segments have generally experienced growth. Factors such as new products, changes in global health spending, regulatory shifts, and disease trends contribute to a constantly changing market, yet one that remains resilient.

Key growing segments attracting industry attention include next-generation sequencing (NGS), personalized medicine, and mass spectrometry. Immunochemistry, point-of-care (POC) testing, and molecular diagnostics are also of significant interest, expected to play a crucial role in the future of IVD. The IVD market remains dynamic, characterized by constant innovations.

"In Vitro Diagnostic (IVD) Trends and Market Update: March 2024" by Kalorama Information provides the most current insights into these trends and others shaping the market. This report reflects the latest information available.

In "In Vitro Diagnostic (IVD) Trends and Market Update: March 2024", you'll discover:

What's Driving Growth in the IVD Market in 2024
What Major Trends are Affecting the Market in 2024
What Product Trends and New Developments Will Shape the IVD Market in 2024

Trends highlighted throughout 2023 and into 2024 include:

Growing interest in multiplex disease testing
Increasing interest in digital diagnostics, combining data and analytics with traditional IVD
Continued advancement of AI technologies
Growth in rapid and POC testing
And much more!

Kalorama Information remains dedicated to examining the IVD market and its evolving landscape, providing precise and up-to-date data through the expertise of its authors and its commitment to excellence in market analysis.

Chapter 1: Worldwide IVD Market - March 2024 Update

IVD Market Demand and Growth
- Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2023
- Table 1-1: Global In Vitro Diagnostic Sales by Product Market (Clinical Chemistry; Immunoassays: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD), 2023 ($M)
- Figure 1-2: IVD Quarterly Segment Performance, by Segment (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Q1 2022-Q4 2023 ($M)
- Figure 1-3: IVD Segment Performance, by Segment (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Total Market Value, 2023 ($M)
COVID-19 Diagnostic Markets
- Table 1-2: COVID-19 Product Sales, by Segment (Immunoassay [Antigen, Serology]; Molecular; Rapid), 2023 ($M)
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market excluding and with COVID-19, 2023 ($M)
- Figure 1-4: IVD Market Distribution, by Segment (COVID-19 Assays and Instruments; Excluding COVID-19 Assays and Instruments), 2023 (%)
- Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2024 ($M)
- Table 1-4: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab, Hematology - Core Lab]; Microbiology (ID/AST); Microbiology (molecular); Coagulation (PT/INR); Histology/cytology, d-dimer; Nucleic acid assays/genetic tests; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth, 2022-2023 (%)
- Figure 1-6: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab, Hematology - Core Lab]; Microbiology (ID/AST); Microbiology (molecular); Coagulation (PT/INR); Histology/cytology, d-dimer; Nucleic acid assays/genetic tests; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth, 2022-2023

Chapter 2: Product Trends and New Developments

Selected New - Q4 2023 and Q1 2024 - Core IVD Product Launches, Developments and Trends
Immunoassay
Molecular
Personalized Medicine and Genetic Testing
POC
Sequencing
Microbiology
Selected COVID-19 Developments - Q4 2023 - Q1 2024
- Figure 2-1: COVID-19 Test Market, by Type (Antigen, Molecular, Rapid, Serology), Q1 2023-Q4 2023 - COVID-19 Testing Wanes ($M)

Chapter 3: Top IVD Market Participant Results

Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth, by Leading Competitors (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Exact Sciences, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific), Change in Sales, 2022-2023 (%)
- Figure 3-2: Changes in Market Distribution for IVD Sales, Top 10 Companies (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Exact Sciences, Hologic, QuidelOrtho, Revvity, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werlen, Others), 2020-2023 [Roche and Abbott Battle for #1 Spot]
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2021-2023 ($M)
Q4 2023, Q1 2024 M&A Activity
- Table 3-1: Selected Diagnostic Market Mergers and Acquisitions Deals, Q4 2023-Q1 2024 ($M)
- Figure 3-4: Count of IVD Industry M&A Deals, by Month, Full Year 2023 and Jan-Feb 2024
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
- Figure 3-5: Abbott Diagnostics Revenue, by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19), Full Year 2022 and 2023 ($M)
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
- Figure 3-6: BD Life Sciences, Revenues by Business, FY End September 30, 2022, and 2023 ($M)
bioMerieux SA
- Table 3-4: bioMerieux Corporate Summary
- Figure 3-7: bioMerieux Clinical Applications, by Segment (Immunoassays, Microbiology, Molecular Biology, Other Lines), Full Year Results, 2022-2023 (Euro-M)
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
- Figure 3-8: Danaher Diagnostic Segment Performance, Full Year Results, 2022-2023 ($M)
Exact Sciences, Inc.
- Table 3-6: Exact Sciences Corporate Summary
- Figure 3-9: Exact Sciences Segment Performance, by Segment Revenue (COVID-19 Testing, Precision Oncology, Screening), Full Year Results, FY 2022-FY 2023 ($M)
Hologic, Inc.
- Table 3-7: Hologic Corporate Summary
- Figure 3-10: Hologic Diagnostic Segment Performance, by Segments (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), Full Year Results, FY 2022-FY 2023 ($M)
QuidelOrtho Corporation
- Table 3-8: QuidelOrtho Corporate Summary
- Figure 3-11: QuidelOrtho Financial Results, by Segment (Immunoassays, Molecular Diagnostics, Point-of-Care, Transfusion Medicine), 2022-2023 ($M)
Roche Diagnostic
- Table 3-9: Roche Diagnostic Corporate Summary
- Figure 3-12: Roche Diagnostics Revenue, by Product Group (Core Lab, Diabetes Care, Molecular, Pathology Lab, Point-of-Care), Full Year Results, 2022-2023 (CHF MN)
Siemens Healthineers
- Table 3-10: Siemens Healthineers Corporate Summary
- Figure 3-13: Siemens Diagnostics Revenue, FY 2022 and FY 2023 (Euro-M)
Sysmex Corporation
- Table 3-11: Sysmex Corporate Summary
- Figure 3-14: Sysmex Revenue, by Product Segment (Clinical Chemistry, FCM, Hematology, Hemostasis, Immunochemistry, Urinalysis, Others), FY 2022, 2023 and 2024 (JPY MN)
Thermo Fisher Scientific
- Table 3-12: Thermo Fisher Scientific Corporate Summary
- Figure 3-15: Thermo Fisher Scientific Business Segment Performance, by Segment (Analytical Instruments, Eliminations, Laboratory Products and Services, Life Sciences Solutions, Specialty Diagnostics), 2022-2023 ($M)